Menactra® Vaccine
MRP ₹ 5,440
Menactra® is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra® is approved for use in individuals from 9 months to 55 years of age. Menactra® does not prevent N meningitidis serogroup B disease.1
DESCRIPTION
Menactra® vaccine is manufactured as a sterile, clear to slightly turbid liquid. Each 0.5 mL dose of vaccine is formulated in sodium phosphate buffered isotonic sodium chloride solution to contain 4 mcg each of meningococcal A, C, Y and W-135 polysaccharides conjugated to approximately 48 mcg of diphtheria toxoid protein carrier.1
COMPOSITION
Menactra®, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar and grown in Watson Scherp media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.1
The four meningococcal components, present as individual serogroup-specific glycoconjugates, compose the final formulated vaccine. No preservative or adjuvant is added during manufacture. Each 0.5 mL dose may contain residual amounts of formaldehyde of less than 2.66 mcg (0.000532%), by calculation. Potency of Menactra® vaccine is determined by quantifying the amount of each polysaccharide antigen that is conjugated to diphtheria toxoid protein and the amount of unconjugated polysaccharide present.1
CLINICAL INFORMATION
Menactra® is approved for use in individuals from 9 months to 55 years of age.
PRIMARY VACCINATION:1
- In children from 9 to 23 months of age, Menactra® is given as a 2-dose series, 3 months apart.
- In individuals from 2 to 55 years of age, Menactra® is given as a single dose.
BOOSTER VACCINATION:1
- A single booster dose of Menactra® may be given to individuals from 15 to 55 years of age at continued risk for meningococcal disease if at least 4 years have elapsed since the prior dose.
STORAGE AND HANDLING
Store at 2° to 8°C (35° to 46°F). DO NOT FREEZE. Frozen/previously frozen product should not be used. Do not use after the expiration date.
References: 1. Menactra® vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.